SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla spurts on inking definitive pact for selling entire 48.22% stake in Jiangsu

10 Dec 2014 Evaluate

Cipla is currently trading at Rs. 647.20, up by 7.35 points or 1.15 % from its previous closing of Rs. 639.85 on the BSE.

The scrip opened at Rs. 639.25 and has touched a high and low of Rs. 651.00 and Rs. 637.40 respectively. So far 29237 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 671.95 on 31-Oct-2014 and a 52 week low of Rs. 366.70 on 24-Feb-2014.

Last one week high and low of the scrip stood at Rs. 667.55 and Rs. 636.80 respectively. The current market cap of the company is Rs. 51868.72 crore.

The promoters holding in the company stood at 36.80 % while Institutions and Non-Institutions held 34.67 % and 27.38 % respectively.

Cipla’s wholly owned subsidiary - Meditab Holdings, Mauritius, has entered into a definitive agreement to sell its entire 48.22% equity interest in Jiangsu Cdymax Pharmaceuticals Company, China (Jiangsu) to an affiliate of one of the other shareholders of Jiangsu, for a total consideration of $18.5 million. The closing of the transaction is subject to receipt of applicable regulatory approvals in China.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.

Cipla Share Price

1238.15 -0.15 (-0.01%)
20-Apr-2026 11:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.50
Dr. Reddys Lab 1237.75
Cipla 1238.15
Zydus Lifesciences 941.45
Lupin 2330.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×